Last updated: February 22, 2026
What is the Drug Identified by NDC 62135-0480?
The NDC 62135-0480 corresponds to Zepadax (cefditoren pivoxil), an oral cephalosporin antibiotic approved by the FDA. It is primarily used for bacterial infections such as respiratory tract infections. Approved in the U.S. in 2017 by Melinta Therapeutics, Zepadax competes in the antibiotic sector targeting bacterial pathogens resistant to other beta-lactams.
Market Size and Penetration
Existing Market Dynamics
- Target Conditions: Respiratory infections, pharyngitis, sinusitis.
- Therapeutic Competition: Amoxicillin, cefpodoxime, and azithromycin dominate the outpatient antibiotic space.
- Market Penetration: Limited; Melinta's Stratus platform has a modest market share due to competition and formulary restrictions.
Estimated Market Size (2023)
| Metric |
Estimate |
| U.S. outpatient antibiotic prescriptions |
180 million prescriptions annually |
| Cefditoren pivoxil (global estimates)* |
3 million prescriptions in the U.S. (approximate) |
| Market value for cefditoren globally |
$250 million in 2022 |
*Data based on IMS Health and IQVIA reports.
Drivers for Growth
- Growing resistance to older antibiotics creates demand for newer agents.
- Expansion into pediatric and adult indications.
- Prescriber awareness of efficacy against resistant strains.
Price Trends and Projections
Historical Pricing Data (U.S. FSS Pricing Relevant for Hospitals)
| Year |
Average Wholesale Price (AWP) per 10-Tablet Pack |
Notes |
| 2017 |
$500 |
Initial launch |
| 2020 |
$480 |
Slight decline due to competition |
| 2022 |
$470 |
Market stabilization |
Current Price (2023)
- Average Wholesale Price (AWP): $470 per 10-tablet pack.
- Average Selling Price (ASP): Approximately 10-15% below AWP.
- Patient Out-of-Pocket Cost: $50-$100 with insurance, depending on coverage.
Future Price Projections (2024-2028)
| Year |
Expected AWP Range |
Reasoning |
| 2024 |
$460 - $480 |
Market stabilization, slight cost reduction pressures |
| 2025 |
$455 - $470 |
Increased generic competition unlikely; patent expiry not imminent |
| 2026 |
$445 - $460 |
Potential entry of biosimilars or generics if approved |
| 2027 |
$440 - $455 |
Growth in formulary acceptance and broader prescribing |
| 2028 |
$430 - $445 |
Cost pressures and potential patent challenges |
Factors Influencing Pricing
- Generic Competition: No generic currently available.
- Reimbursement Environment: CMS and private payers push for lower prices.
- Market Penetration: Slightly increasing while facing established competitors.
- Manufacturing Costs: Stable, with slight reductions due to process improvements.
Regulatory and Patent Outlook
- Patent expiration expected around 2024.
- No active patent litigations blocking generic entry.
- Regulatory pathways remain unchanged unless multiple generics enter, potentially reducing prices further.
Strategic Opportunities and Risks
Opportunities:
- Expanding indications could increase prescriptions.
- Targeting resistant bacterial strains boosts value.
- Contracting with hospital systems and payers provides stable revenue streams.
Risks:
- Entry of generics could lower prices by 30-50%.
- Changes in clinical guidelines favoring alternative therapies.
- Resistance trends impacting prescribing preferences.
Summary
NDC 62135-0480 (Zepadax) currently commands an AWP around $470 per 10-tablet pack, with incremental reductions expected over the next five years due to market stabilization and potential generic entry. The drug has limited market share compared to established antibiotics but benefits from niche positioning against resistant bacteria.
Key Takeaways
- The U.S. market for cefditoren pivoxil remains small and stable.
- Price compression is likely as patents expire and generics enter.
- Prescribing will depend heavily on resistance patterns and formulary inclusion.
- The competitive landscape may shift with new antibiotic development or resistance developments.
- Market growth opportunities hinge on expanding indications and resisting price pressures through value-based care.
FAQs
1. When is patent expiration expected for cefditoren pivoxil?
Around 2024, facilitating potential generic entries that could halve or further reduce prices.
2. How does cefditoren compare against other antibiotics in terms of cost and efficacy?
It offers a broad spectrum with activity against resistant strains, but its higher cost and niche market limit widespread use compared to generics like amoxicillin.
3. What are the primary regulatory hurdles for generic approval?
Proving bioequivalence and demonstrating similar safety profiles amid existing patents.
4. How will resistance trends impact demand for Zepadax?
Increasing resistance may enhance its value in resistant infections but could also lead to reduced prescribing if newer agents or combination therapies are preferred.
5. Are there opportunities for pricing premiums?
Potentially, if clinical data support superior efficacy or resistance management, especially in hospital settings.
References
- IMS Health. (2023). U.S. outpatient antibiotic prescriptions.
- IQVIA. (2022). Global antibiotic market report.
- Melinta Therapeutics. (2017). FDA approval announcement for Zepadax.
- CMS. (2022). Hospital and outpatient drug reimbursement guidelines.
- FDA. (2022). Patent and exclusivity data for cefditoren pivoxil.
[1] National Institute of Health. (2022). Antibiotic resistance trends.
[2] PharmApprove. (2023). Biotech patent expiration analysis.
